Company / Shareholders' Equity
RAPT Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$189.9M
FY2024
5-year range
$104.2M / $245.2M
FY2020-FY2024
Trend
+29.2%
vs FY2023
Sector context
#153 of 214
Health Care
What the data says
At $190M, RAPT Therapeutics, Inc.'s shareholders' equity ranks #153 of 214 in the Health Care sector. Declined from $245M to $190M over the past 2 years.
Based on SEC 10-K filings.
$190M in FY2024 with a 5-year CAGR of +21.0%.
Declined from $245M to $190M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- +21.0%
- 10-Year CAGR
- -
Sector benchmark
#153 of 214 in Health CareTop 71% of 214This company $189.9M Sector average $2.6B
▼
-92.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.0%, indicating consistent growth.
- In FY2024, shareholders' equity increased 29.2% year-over-year.
- Ranks #153 out of 214 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $189.9M | +29.2% |
| FY2023 | $147.0M | -40.0% |
| FY2022 | $245.2M | +31.5% |
| FY2021 | $186.4M | +78.9% |
| FY2020 | $104.2M | +42.5% |
| FY2019 | $73.1M | +175.3% |
| FY2018 | -$97.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026